Literature DB >> 21482811

Route to three-dimensional fragments using diversity-oriented synthesis.

Alvin W Hung1, Alex Ramek, Yikai Wang, Taner Kaya, J Anthony Wilson, Paul A Clemons, Damian W Young.   

Abstract

Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chemical ligands as starting points for drug-discovery pursuits. The increasing number of clinical candidate drugs developed using FBDD approaches is a testament of the efficacy of this approach. The success of fragment-based methods is highly dependent on the identity of the fragment library used for screening. The vast majority of FBDD has centered on the use of sp(2)-rich aromatic compounds. An expanded set of fragments that possess more 3D character would provide access to a larger chemical space of fragments than those currently used. Diversity-oriented synthesis (DOS) aims to efficiently generate a set of molecules diverse in skeletal and stereochemical properties. Molecules derived from DOS have also displayed significant success in the modulation of function of various "difficult" targets. Herein, we describe the application of DOS toward the construction of a unique set of fragments containing highly sp(3)-rich skeletons for fragment-based screening. Using cheminformatic analysis, we quantified the shapes and physical properties of the new 3D fragments and compared them with a database containing known fragment-like molecules.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482811      PMCID: PMC3084099          DOI: 10.1073/pnas.1015271108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Target-oriented and diversity-oriented organic synthesis in drug discovery.

Authors:  S L Schreiber
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

2.  A 'rule of three' for fragment-based lead discovery?

Authors:  Miles Congreve; Robin Carr; Chris Murray; Harren Jhoti
Journal:  Drug Discov Today       Date:  2003-10-01       Impact factor: 7.851

3.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

Review 4.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

5.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase.

Authors:  Alvin W Hung; H Leonardo Silvestre; Shijun Wen; Alessio Ciulli; Tom L Blundell; Chris Abell
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

6.  Drug discovery: A question of library design.

Authors:  Philip J Hajduk; Warren R J D Galloway; David R Spring
Journal:  Nature       Date:  2011-02-03       Impact factor: 49.962

7.  Self-selection in olefin cross-metathesis: the effect of remote functionality.

Authors:  Brian R McNaughton; Kevin M Bucholtz; Ana Camaaño-Moure; Benjamin L Miller
Journal:  Org Lett       Date:  2005-02-17       Impact factor: 6.005

8.  An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors.

Authors:  Lisa A Marcaurelle; Eamon Comer; Sivaraman Dandapani; Jeremy R Duvall; Baudouin Gerard; Sarathy Kesavan; Maurice D Lee; Haibo Liu; Jason T Lowe; Jean-Charles Marie; Carol A Mulrooney; Bhaumik A Pandya; Ann Rowley; Troy D Ryba; Byung-Chul Suh; Jingqiang Wei; Damian W Young; Lakshmi B Akella; Nathan T Ross; Yan-Ling Zhang; Daniel M Fass; Surya A Reis; Wen-Ning Zhao; Stephen J Haggarty; Michelle Palmer; Michael A Foley
Journal:  J Am Chem Soc       Date:  2010-11-10       Impact factor: 15.419

9.  Decomposition of a key intermediate in ruthenium-catalyzed olefin metathesis reactions.

Authors:  Soon Hyeok Hong; Michael W Day; Robert H Grubbs
Journal:  J Am Chem Soc       Date:  2004-06-23       Impact factor: 15.419

10.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

View more
  48 in total

1.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

2.  Synthesis of a Library of 1,5,2-Dithiazepine 1,1-Dioxides. Part 2: Routes to Bicyclic Sultams.

Authors:  Qin Zang; Salim Javed; Aihua Zhou; Chris A Knudtson; Danse Bi; Fatima Z Basha; Paul R Hanson
Journal:  Heterocycles       Date:  2012-12-31       Impact factor: 0.831

3.  The 'rule of three' for fragment-based drug discovery: where are we now?

Authors:  Harren Jhoti; Glyn Williams; David C Rees; Christopher W Murray
Journal:  Nat Rev Drug Discov       Date:  2013-07-12       Impact factor: 84.694

4.  A three-stage biophysical screening cascade for fragment-based drug discovery.

Authors:  Ellene H Mashalidis; Paweł Śledź; Steffen Lang; Chris Abell
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections.

Authors:  Paul A Clemons; J Anthony Wilson; Vlado Dančík; Sandrine Muller; Hyman A Carrinski; Bridget K Wagner; Angela N Koehler; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

6.  Natural-product-derived fragments for fragment-based ligand discovery.

Authors:  Björn Over; Stefan Wetzel; Christian Grütter; Yasushi Nakai; Steffen Renner; Daniel Rauh; Herbert Waldmann
Journal:  Nat Chem       Date:  2012-12-02       Impact factor: 24.427

7.  Translational synthetic chemistry.

Authors:  Sarathy Kesavan; Lisa A Marcaurelle
Journal:  Nat Chem Biol       Date:  2013-04       Impact factor: 15.040

8.  Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β.

Authors:  Yikai Wang; Jean-Yves Wach; Patrick Sheehan; Cheng Zhong; Chenyang Zhan; Richard Harris; Steven C Almo; Joshua Bishop; Stephen J Haggarty; Alexander Ramek; Kayla N Berry; Conor O'Herin; Angela N Koehler; Alvin W Hung; Damian W Young
Journal:  ACS Med Chem Lett       Date:  2016-07-14       Impact factor: 4.345

9.  Re-engineering natural products to engage new biological targets.

Authors:  Stephen E Motika; Paul J Hergenrother
Journal:  Nat Prod Rep       Date:  2020-11-18       Impact factor: 13.423

Review 10.  Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.

Authors:  Kenneth K Hallenbeck; David M Turner; Adam R Renslo; Michelle R Arkin
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.